Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of KVD824 MR Formulations in Healthy Subjects
NCT05118958Phase 1Completed
- Sponsor
- KalVista Pharmaceuticals
- Start
- May 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KVD824 in hereditary angioedema (HAE) (12 arms), sponsored by KalVista Pharmaceuticals. Primary endpoints: Lag Time at Day 14, Time to Maximum Concentration at Day 14 and 5 more. Started May 2020; status: completed.
02
Drugs
KVD824
03
Conditions
hereditary angioedema (HAE)
Beyond the preview
Go deeper on NCT05118958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05118958.